Clinical trial
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red…
NCT00235391 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00235391 |
|---|---|
| Title | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload |
| Official title | A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis |
| Intervention type | Drug |
| Interventions | Deferasirox |
| Enrollment | 1,683 |
| Start date | Oct 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Oct 10, 2005 |
| Last update posted | Jun 7, 2011 |
| Countries | Belgium, Canada, Germany, Greece, Italy, Netherlands, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: